logo-loader
viewCytoDyn Inc.

Full interview: CytoDyn reveals plans for its Phase 2 basket trial to treat 22 different solid tumor cancers

 

CytoDyn Inc (OTCMKTS:CYDY) CEO Nader Pourhassan tells Proactive the company will begin its Phase 2 clinical trial of leronlimab (PRO 140) for the treatment of about 22 different solid tumor cancers in a basket trial.

Pourhassan also updated on its anticipated BLA submission for its HIV combination therapy, as well as efforts to develop a drug to treat the coronavirus.

Quick facts: CytoDyn Inc.

Price: 2.97 USD

OTCQB:CYDY
Market: OTCQB
Market Cap: $1.43 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CytoDyn Inc. named herein, including the promotion by the Company of CytoDyn Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

CytoDyn to work with Mexican National Institutes of Health to treat...

CytoDyn Inc (OTCQB:CYDY) CEO Nader Pourhassan tells Proactive the biotech has plans to work with the Mexican National Institutes of Health on a trial of leronlimab for severe coronavirus patients in the country. Pourhassan says the initial trial is expected to include about 30 patients. After...

2 weeks ago

2 min read